The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence
- PMID: 15720937
- PMCID: PMC1463190
The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence
Abstract
Background: Opiate dependence is a major health and social issue in many countries. A mainstay of therapy has been methadone maintenance treatment, but other treatments, particularly buprenorphine, are increasingly being considered.
Aim: To conduct a systematic review to synthesise and critically appraise the evidence on the effectiveness of community maintenance programmes with methadone or buprenorphine in treating opiate dependence.
Method: A systematic review of databases, journals and the grey literature was carried out from 1990-2002. Inclusion criteria were: community-based, randomised controlled trials of methadone and/or buprenorphine for opiate dependence involving subjects who were aged 18 years old or over.
Results: Trials were set in a range of countries, employed a variety of comparators, and suffered from a number of biases. The evidence indicated that higher doses of methadone and buprenorphine are associated with better treatment outcomes. Low-dose methadone (20 mg per day) is less effective than buprenorphine (2-8 mg per day). Higher doses of methadone (>50-65 mg per day) are slightly more effective than buprenorphine (2-8 mg per day). There was some evidence that primary care could be an effective setting to provide this treatment, but such evidence was sparse.
Conclusion: The literature supports the effectiveness of substitute prescribing with methadone or buprenorphine in treating opiate dependence. Evidence is also emerging that the provision of methadone or buprenorphine by primary care physicians is feasible and may be effective.
Figures
Comment in
-
Buprenorphine versus methadone--safety first?Br J Gen Pract. 2005 Mar;55(512):232-3. Br J Gen Pract. 2005. PMID: 15808047 Free PMC article. No abstract available.
-
Qualifications.Br J Gen Pract. 2005 Apr;55(513):313. Br J Gen Pract. 2005. PMID: 15826440 Free PMC article. No abstract available.
-
Methadone vs buprenorphine.Br J Gen Pract. 2005 Jul;55(516):558-9; author reply 559. Br J Gen Pract. 2005. PMID: 16004754 Free PMC article. No abstract available.
Similar articles
-
Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. doi: 10.3310/hta11090. Health Technol Assess. 2007. PMID: 17313907
-
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.Cochrane Database Syst Rev. 2004;(3):CD002207. doi: 10.1002/14651858.CD002207.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. doi: 10.1002/14651858.CD002207.pub3. PMID: 15266465 Updated.
-
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.Cochrane Database Syst Rev. 2003;(2):CD002207. doi: 10.1002/14651858.CD002207. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2004;(3):CD002207. doi: 10.1002/14651858.CD002207.pub2. PMID: 12804429 Updated.
-
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.Cochrane Database Syst Rev. 2002;(4):CD002207. doi: 10.1002/14651858.CD002207. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2003;(2):CD002207. doi: 10.1002/14651858.CD002207. PMID: 12519569 Updated.
-
Buprenorphine for the management of opioid withdrawal.Cochrane Database Syst Rev. 2000;(3):CD002025. doi: 10.1002/14651858.CD002025. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(2):CD002025. doi: 10.1002/14651858.CD002025. PMID: 10908521 Updated.
Cited by
-
Buprenorphine versus methadone--safety first?Br J Gen Pract. 2005 Mar;55(512):232-3. Br J Gen Pract. 2005. PMID: 15808047 Free PMC article. No abstract available.
-
Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials.BMC Med. 2022 Jul 12;20(1):224. doi: 10.1186/s12916-022-02423-z. BMC Med. 2022. PMID: 35818057 Free PMC article.
-
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.Addict Sci Clin Pract. 2022 Jul 18;17(1):36. doi: 10.1186/s13722-022-00317-2. Addict Sci Clin Pract. 2022. PMID: 35850782 Free PMC article. Clinical Trial.
-
Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment.Subst Abuse. 2022 Jul 22;16:11782218221112502. doi: 10.1177/11782218221112502. eCollection 2022. Subst Abuse. 2022. PMID: 35903309 Free PMC article.
-
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.Drug Alcohol Depend. 2010 Jan 1;106(1):56-60. doi: 10.1016/j.drugalcdep.2009.07.013. Epub 2009 Aug 29. Drug Alcohol Depend. 2010. PMID: 19717249 Free PMC article.
References
-
- Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195–206. - PubMed
-
- Mattick RP, Kimber J, Breen C, Davoli M. The Cochrane Library. Issue 4. Oxford: Update Software; 2003. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Cochrane Review) In: Cochrane Collaboration. - PubMed
-
- Cochrane Collaboration. Cochrane reviewers' handbook 4.1.4. Updated October 2001. http://www.cochrane.org/resources/handbook/index.htm (accessed 22 December 2004.)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical